乌司他丁辅助治疗重症感染性休克的价值分析

目的探究临床用乌司他丁辅助治疗重症感染性休克的治疗效果。方法90例重症感染性休克患者,随机分为观察组与对照组,每组45例。对照组患者采用西医常规治疗,观察组患者在对照组基础上联合乌司他丁治疗。比较两组患者治疗效果、体温情况、感染情况以及治疗前后白细胞计数、白细胞介素-6(IL-6)水平、格拉斯哥昏迷量表(GCS)评分、急性生理功能和慢性健康状况评分系统Ⅱ(APACHEⅡ)评分。结果治疗后,观察组白细胞计数(7.34±1.32)×10^9/L低于对照组的(9.41±1.16)×10^9/L,差异具有统计学意义(P<0.05)。治疗后,观察组高热、感染体征发生率分别为97.78%、86.67%,均高于对照组的82.22%、62.22%,差异具有统计学意义(P<0.05);观察组体温恢复时间、感染消失时间分别为(7.19±1.39)、(3.88±0.89)d,均短于对照组的(9.81±1.88)、(10.76±1.57)d,差异具有统计学意义(P<0.05)。观察组患者血清IL-6为(4.27±0.95)μg/L低于对照组的(9.58±1.07)μg/L,差异具有统计学意义(P<0.05)。观察组患者GCS评分和APACHEⅡ评分较治疗前均有所改善,GCS评分(8.19±1.59)分、APACHEⅡ评分(8.83±0.82)分均优于对照组的(6.81±1.82)、(14.71±3.52)分,差异均具有统计学意义(P<0.05)。观察组患者治疗总有效率95.56%明显高于对照组的77.78%,差异具有统计学意义(χ^2=6.154,P<0.05)。结论乌司他丁具有较好的抗炎效果,与西医治疗相结合可以提高临床疗效,加快重症感染性休克患者退热速度,缩短感染时间,降低白细胞计数及血清IL-6水平,改善GCS评分和APACHEⅡ评分,临床疗效较好。

The value of ulinastatin in the treatment of severe septic shock

Objective To investigate the therapeutic effect of ulinastatin in the treatment of severe septic shock.Methods A total of 90 severe septic shock patients were randomly divided into observation group and control group,with 45 cases in each group.The control group was treated by conventional Western medicine,and the observation group was treated by ulinastatin on the basis of the control group.The therapeutic effect,body temperature recovery time,infection disappearance time,white blood cell count,interleukin-6(IL-6)level,Glasgow coma scale(GCS)score,acute physiology and chronic health evaluationⅡ(APACHEⅡ)score were compared between the two groups.Results After treatment,the white blood cell count(7.34±1.32)×10^9/L of the observation group was lower than that of the control group(9.41±1.16)×10^9/L,and the difference was statistically significant(P<0.05).After treatment,the body temperature recovery time and infection disappearance time of the observation group were(7.19±1.39)and(3.88±0.89)d,which were all shorter than those of the control group(9.81±1.88)and(10.76±1.57)d,and the difference was statistically significant(P<0.05).After treatment,the serum IL-6 of the observation group was(4.27±0.95)μg/L,which was lower than that of the control group(9.58±1.07)μg/L,and the difference was statistically significant(P<0.05).GCS score and APACHEⅡscore of the two groups were all better than those before treatment of the same group,and GCS score(8.19±1.59)points and APACHEⅡscore(8.83±0.82)points of the observation group were all better than those of the control group(6.81±1.82)and(14.71±3.52)points,and the difference was statistically significant(P<0.05).The total effective rate of the treatment 95.56%of the observation group was obviously higher than that of the control group 77.78%,and the difference was statistically significant(χ^2=6.154,P<0.05).Conclusion Ulinastatin has a good anti-inflammatory effect.Combined with Western medicine,it can improve the clinical efficacy,accelerate the speed of fever reduction in severe septic shock patients,shorten the infection time,reduce the white blood cell count and serum IL-6 levels,improve the GCS score and APACHEⅡscore.The clinical efficacy is good.